open access

Vol 71, No 5 (2020)
Original paper
Published online: 2020-08-03
Submitted: 2020-04-01
Accepted: 2020-06-11
Get Citation

The effects of testosterone replacement therapy in men with age-dependent hypogonadism on body composition, and serum levels of leptin, adiponectin, and C-reactive protein

Piotr Dudek, Jarosław Kozakowski, Wojciech Zgliczyński
DOI: 10.5603/EP.a2020.0048
·
Pubmed: 32797473
·
Endokrynologia Polska 2020;71(5):382-387.

open access

Vol 71, No 5 (2020)
Original Paper
Published online: 2020-08-03
Submitted: 2020-04-01
Accepted: 2020-06-11

Abstract

Introduction: Age-related hypogonadism in men leads to abnormal body composition development and overproduction of inflammatory cytokines, and thus has atherogenic and potentially cancer promoting effects. The aim of the study was to assess the effect of agedependent testosterone deficiency replacement in men on body composition, serum leptin, adiponectin, and C-reactive protein levels.

Material and methods: Men aged 50–65 years (56.0 ± 5.7, average ± SD), with total testosterone levels < 4 ng/mL, and clinical symptoms of hypogonadism were divided into two groups of 20 men and treated with testosterone (200 mg/two weeks intramuscularly) or placebo during 12 months.

Results: Twelve months of treatment with testosterone led to body mass index (BMI) and fat mass (FM) decrease from 26.6 ± 2.1 to 26.1 ± 1.8 kg/m2, p < 0.05, and from 17.0 ± 4.4 to 15.6 ± 4.0 kg, p < 0.05, respectively. Body mass index and FM did not change in placebo-receiving subjects. Serum leptin and highly selective C-reactive protein (hsCRP) levels in testosterone group decreased from 6.2 ± 1.4 to 4.0 ± 1.2 μg/L, p < 0.05, and from 1.4 ± 1.2 to 1.0 ± 1.0 mg/L, p < 0.05 after 12 months, respectively. Adiponectin increased from 7.6 ± 2.5 μg/mL to 9.4 ± 2.8 μg/mL, p < 0.05 in the same time. In the placebo group serum leptin, adiponectin, and hsCRP levels did not change significantly.

Conclusions: Testosterone replacement in men with age-related hypogonadism causes a decrease in body mass index, fat mass, serum leptin, and C-reactive protein levels and increases serum adiponectin levels. 

Abstract

Introduction: Age-related hypogonadism in men leads to abnormal body composition development and overproduction of inflammatory cytokines, and thus has atherogenic and potentially cancer promoting effects. The aim of the study was to assess the effect of agedependent testosterone deficiency replacement in men on body composition, serum leptin, adiponectin, and C-reactive protein levels.

Material and methods: Men aged 50–65 years (56.0 ± 5.7, average ± SD), with total testosterone levels < 4 ng/mL, and clinical symptoms of hypogonadism were divided into two groups of 20 men and treated with testosterone (200 mg/two weeks intramuscularly) or placebo during 12 months.

Results: Twelve months of treatment with testosterone led to body mass index (BMI) and fat mass (FM) decrease from 26.6 ± 2.1 to 26.1 ± 1.8 kg/m2, p < 0.05, and from 17.0 ± 4.4 to 15.6 ± 4.0 kg, p < 0.05, respectively. Body mass index and FM did not change in placebo-receiving subjects. Serum leptin and highly selective C-reactive protein (hsCRP) levels in testosterone group decreased from 6.2 ± 1.4 to 4.0 ± 1.2 μg/L, p < 0.05, and from 1.4 ± 1.2 to 1.0 ± 1.0 mg/L, p < 0.05 after 12 months, respectively. Adiponectin increased from 7.6 ± 2.5 μg/mL to 9.4 ± 2.8 μg/mL, p < 0.05 in the same time. In the placebo group serum leptin, adiponectin, and hsCRP levels did not change significantly.

Conclusions: Testosterone replacement in men with age-related hypogonadism causes a decrease in body mass index, fat mass, serum leptin, and C-reactive protein levels and increases serum adiponectin levels. 

Get Citation

Keywords

aging male; hormonal supplementation; fat mass; cytokines

About this article
Title

The effects of testosterone replacement therapy in men with age-dependent hypogonadism on body composition, and serum levels of leptin, adiponectin, and C-reactive protein

Journal

Endokrynologia Polska

Issue

Vol 71, No 5 (2020)

Article type

Original paper

Pages

382-387

Published online

2020-08-03

DOI

10.5603/EP.a2020.0048

Pubmed

32797473

Bibliographic record

Endokrynologia Polska 2020;71(5):382-387.

Keywords

aging male
hormonal supplementation
fat mass
cytokines

Authors

Piotr Dudek
Jarosław Kozakowski
Wojciech Zgliczyński

References (21)
  1. Stanworth RD, Jones TH. Testosterone for the aging male; current evidence and recommended practice. Clin Interv Aging. 2008; 3(1): 25–44.
  2. Payne GA, Tune JD, Knudson JD. Leptin-induced endothelial dysfunction: a target for therapeutic interventions. Curr Pharm Des. 2014; 20(4): 603–608.
  3. Jardé T, Perrier S, Vasson MP, et al. Molecular mechanisms of leptin and adiponectin in breast cancer. Eur J Cancer. 2011; 47(1): 33–43.
  4. Ouchi N, Ohishi M, Kihara S, et al. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension. 2003; 42(3): 231–234.
  5. Kumada M, Kihara S, Sumitsuji S, et al. Osaka CAD Study Group. Coronary artery disease. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol. 2003; 23(1): 85–89.
  6. Calabro P, Chang DW, Willerson JT, et al. Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. J Am Coll Cardiol. 2005; 46(6): 1112–1113.
  7. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000; 342(12): 836–843.
  8. Diver MJ, Imtiaz KE, Ahmad AM, et al. Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men. Clin Endocrinol (Oxf). 2003; 58(6): 710–717.
  9. Mazess RB, Barden HS, Bisek JP, et al. Dual-energy x-ray absorptiometry for total-body and regional bone-mineral and soft-tissue composition. Am J Clin Nutr. 1990; 51(6): 1106–1112.
  10. Finkelstein JS, Lee H, Burnett-Bowie SAM, et al. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013; 369(11): 1011–1022.
  11. Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol. 2010; 316(2): 129–139.
  12. Luukkaa V, Pesonen U, Huhtaniemi I, et al. Inverse correlation between serum testosterone and leptin in men. J Clin Endocrinol Metab. 1998; 83(9): 3243–3246.
  13. Van Den Saffele JK, Goemaere S, De Bacquer D, et al. Serum leptin levels in healthy ageing men: are decreased serum testosterone and increased adiposity in elderly men the consequence of leptin deficiency? Clin Endocrinol (Oxf). 1999; 51(1): 81–88.
  14. Haffner SM, Miettinen H, Karhapää P, et al. Leptin concentrations, sex hormones, and cortisol in nondiabetic men. J Clin Endocrinol Metab. 1997; 82(6): 1807–1809.
  15. Wabitsch M, Blum WF, Muche R, et al. Contribution of androgens to the gender difference in leptin production in obese children and adolescents. J Clin Invest. 1997; 100(4): 808–813.
  16. Ghantous CM, Azrak Z, Hanache S, et al. Differential Role of Leptin and Adiponectin in Cardiovascular System. Int J Endocrinol. 2015; 2015: 534320.
  17. Srikanthan K, Feyh A, Visweshwar H, et al. Systematic Review of Metabolic Syndrome Biomarkers: A Panel for Early Detection, Management, and Risk Stratification in the West Virginian Population. Int J Med Sci. 2016; 13(1): 25–38.
  18. Booth A, Magnuson A, Fouts J, et al. Adipose tissue, obesity and adipokines: role in cancer promotion. Horm Mol Biol Clin Investig. 2015; 21(1): 57–74.
  19. Page ST, Herbst KL, Amory JK, et al. Testosterone administration suppresses adiponectin levels in men. J Androl. 2005; 26(1): 85–92.
  20. Frederiksen L, Højlund K, Hougaard DM, et al. Testosterone therapy decreases subcutaneous fat and adiponectin in aging men. Eur J Endocrinol. 2012; 166(3): 469–476.
  21. Saad F, Aversa A, Isidori AM, et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol. 2011; 165(5): 675–685.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl